Hansa Biopharma — Juni 2024
-
Kursudviklingen for Sarepta Therapeutics efter børstid kommer ikke til at blive afspejlet direkte, da DMD-aftalen kun udgør en mindre del/værdi af Hansa Biopharmas portefølje, som eksempelvis nævnt i en tidligere analyse fra Penser Access (nu overtaget af Carnegie).
-
Sarepta Therapeutics surges 36% after-hours following expanded FDA approval
-
Det bliver spændende.
-
Sarepta's DMD gene therapy secures much-sought-after label expansion https://firstwordpharma.com/story/5868924
-
Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval
Sarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its Duchenne muscular dystrophy gene therapy.
Investor's Business Daily (www.investors.com)
"The approval expands the market for Elevidys by more than tenfold, Leerink Partners analyst Joseph Schwartz said. Under the original approval, about 7% of patients were eligible for the gene therapy. Now, about 80% are eligible, he said in a report."
-
De bruger det ikke endnu, du har svaret her: https://clinicaltrials.gov/study/NCT06241950?term=Sarepta&aggFilters=status:act&rank=6&tab=history
-
Det er ca. 14% af patienter som er potentielle. Ca. 3-400 nyfødte drengebørn i US om året som har DMD. Imlifidase er endnu ikke godkendt i US. Roche står for udrulning af Sareptas genterapi i Europ. Hansa modtager ca 10% i fee,
hvilket svarer til ca. -
Expanded label for Sarepta's DMD therapy Elevidys seen as 'best-case scenario' https://firstwordpharma.com/story/5869033
-
Interview med CCO Matthew Shaulis & US President of Hansa Biopharma
Episode 03 - Matthew Shaulis, CCO & US President of Hansa Bio
Listen to this episode from The BioHub - by Avetix on Spotify. Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We're super excited to welcome a phenomenal guest, Matthew Shaulis! Matthew is the Chief Commercial Officer and US President of Hansa Biopharma. With over 20 years of experience in the pharmaceutical industry, he's held top executive roles at giants like Pfizer and Teva. Now, he's leading the charge at Hansa, bringing groundbreaking treatments for rare immunological diseases to the US. We're diving into some fascinating topics today! We'll explore the incredible growth of Hansa Biopharma, what makes it stand out, and the unique challenges and opportunities in the biotech world. Matthew will share his insights on making tough business decisions, navigating the unpredictable biotech landscape, and the exciting milestones ahead for Hansa. Plus, we'll get a peek into his personal journey and what fuels his impressive career. Enjoy and stay tuned
Spotify (open.spotify.com)
(Spotify - The Biohub)
"We're super excited to welcome a phenomenal guest, Matthew Shaulis!
Matthew is the Chief Commercial Officer and US President of Hansa Biopharma. With over 20 years of experience in the pharmaceutical industry, he's held top executive roles at giants like Pfizer and Teva." -
Kort video:
Zealand Pharma, Novo, Gubra, Bavarian, ALK , Hansa Biopharma https://proinvestor.com/boards/121107
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind